DOCSLIB.ORG

Hydroxychloroquine and Sulphasalazine Alone and Ann Rheum Dis: First Published As 10.1136/Ard.52.10.711 on 1 October 1993

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hydroxychloroquine and Sulphasalazine Alone and Ann Rheum Dis: First Published As 10.1136/Ard.52.10.711 on 1 October 1993 Annals of the Rheumatic Diseases 1993; 52: 711-715 71 Hydroxychloroquine and sulphasalazine alone and Ann Rheum Dis: first published as 10.1136/ard.52.10.711 on 1 October 1993. Downloaded from in combination in rheumatoid arthritis: a randomised double blind trial Karen Lisbeth Faarvang, Charlotte Egsmose, Peter Kryger, Jan P0denphant, Margrethe Ingeman-Nielsen, Troels M0rk Hansen Abstract and hydroxychloroquine was superior to Objectives-To compare the effects of treatment with a single drug. The two drugs hydroxychloroquine and sulphasalazine were chosen because of their low incidence of alone and in combination in rheumatoid serious side effects. In addition, we aimed to arthritis. determine whether previous treatment with Methods-A six month randomised, gold salts or penicillamine affected the multicentre, double blind trial with three outcome. Finally, the selection of patients for parallel groups was performed. Ninety one the study from the total population of patients outpatients with active rheumatoid with RA at the three participating rheumato- arthritis were included. Monthly assess- logical clinics was recorded. ments of erythrocyte sedimentation rate, morning stiffness, number of swollen joints, a pain score, and global assess- Patients and methods ments were carried out. Radiographs of PATIENTS hands and wrists were taken before and During the inclusion period 776 patients with after the trial. RA were registered in the three participating Results-Sixty two patients completed the departments. Ninety one of these met the study. The 29 withdrawals caused no criteria for inclusion in the trial. They all had evident bias, and there was no difference RA defined according to the American in side effects among the three groups. All Rheumatism Association 1958 criteria.' The Department of variables improved significantly with mean age was 61 years (range 18-82) and the Rheumatology, Kong time. Patients treated with a combination male to female ratio was 35:56. The mean Christian d X's ofhydroxychloroquine and sulphasalazine duration of RA was 6-3 years (range and http://ard.bmj.com/ Gigthospital, DK-6300 0-37) Graasten, Denmark responded better and faster than those 71% belonged to Steinbrocker's functional K L Faarvang treated with hydroxychloroquine alone, class I and 29% to class II.2 All the patients had T M Hansen but there was no statistically significant active disease-that is, at least three swollen Department of difference between the combination joints and at least two of the following three Rheumatology, treatment and treatment Glostrup Hospital, single drug with criteria: (a) a minimum of six tender joints; (b) University of sulphasalazine or between treatment with duration of morning stiffness of 45 minutes or Copenhagen, DK-2600 hydroxychloroquine and sulphasalazine longer; or (c) an erythrocyte sedimentation rate on September 25, 2021 by guest. Protected copyright. Glostrup, Denmark given alone. (ESR) greater than 28 mm/h. Patients were C Egsmore Conclusion-The present results do not excluded based on the criteria given in table 1. Department of Rheumatology, support a recommendation to use a The patients were randomised using a table Hvidovre Hospital, combination of hydroxychloroquine and of random numbers of three parallel groups University of sulphasalazine in the treatment of and a double blind technique was used. The Copenhagen, DK-2650 rheumatoid Hvidovre, Denmark arthritis. study was performed in accordance with the P Kryger Helsinki declaration II and was approved by J Podenphant (Ann Rheum Dis 1993; 52: 711-715) the local ethical committees. Department of Radiology, Aalborg Hospital, DK-9100 Aalborg, Denmark A combination of two or more disease M modifying antirheumatic drugs might have Table 1 No ofpatients excluded according to the criteria Ingeman-Nielsen used in this study Department of advantages compared with treatment with a Rheumatology, Herlev single drug in the management of rheumatoid Lack of disease activity 408 Hospital, University of arthritis (RA). Little is known about the Functional class III or IV (Steinbrocker2) 117 Copenhagen, DK-2730 Age < 18 years 4 Herlev, Denmark biological effects of disease modifying anti- Pregnant or lactating women 4 rheumatic but Previous treatment with HC or SASP, or both 233 K L Faarvang drugs, possible differences in Treatment with disease modifying antirheumatic T M Hansen their actions might be used in combination drugs within one month 328 Malignancies 1 Correspondence to: treatment through either additive or synergistic Dr Karen Lisbeth Faarvang, Glucocorticosteroids within last six weeks 158 Department of effects. Potential advantages could be Refused participation 15 Rheumatology 53Q1, Herlev increased effect, a faster onset of the effect, or Allergic to the drugs in question, or eye disease Hospital, DK-2730 Herlev, which contraindicates HC 6 Denmark. a greater response rate. The purpose was Each patient could be recorded with more than one exclusion Accepted for publication of this investigation to criterion. The total number of excluded patients was 685. 28 June 1993 study whether a combination of sulphasalazine HC=Hydroxychloroquine; SASP=sulphasalazine. 712 Faarvang, Egsmose, Kryger, P0denphant, Ingeman-Nielsen, Hansen TREATMENT sets of images was compared for marked The patients were allocated to six months of progression of the number or size of lesions. treatment with (a) hydroxychloroquine 250 This method has been used previously and has Ann Rheum Dis: first published as 10.1136/ard.52.10.711 on 1 October 1993. Downloaded from mg/day and placebo (resembling enteric coated been described in detail elsewhere.3 Routine sulphasalazine 2 g/day), (b) sulphasalazine 2 laboratory tests were performed once a month g/day (enteric coated tablets) and placebo and an ophthalmological examination was (resembling hydroxychloroquine 250 mg/day), carried out every third month. Previous or (c) hydroxychloroquine 250 mg/day and treatment with gold salts or penicillamine, or sulphasalazine 2 g/day (enteric coated tablets). both, was recorded. The patients were allowed to continue current treatment with non-steroidal anti-inflam- matory drugs, paracetamol, and dextro- SAMPLE SIZE AND STATISTICAL METHODS propoxyphene during the study. We wanted to be reasonably sure of finding significant differences in the trial if there was a difference of at least 25% between two INVESTIGATIONS treatments. For this reason we set 2ot=5% and Before onset, and once a month throughout the power to 80%. The standard deviation was the trial, disease activity was assessed by the estimated to be 30%. Considering also the same observer in each centre. Assessments possibility of a dropout rate of up to 30% we consisted of a recording of the ESR, the estimated that each group should comprise duration of morning stiffness, number of 30-35 patients at randomisation. swollen joints (0-40), a pain score (none=0, The statistical evaluation of the results was mild= 1, moderate=2, severe=3, very carried out using a non-parametric model severe=4), and the global assessments of the corresponding to one and two way ANOVA.3 patients and doctors (better= 1, unchanged=o, The factors were treatment and time (repeated worse=-1 with respect to the previous visit). measures). In addition, parametric analyses Side effects were noted. Radiological were performed; only p values <0 05 were examinations were performed blindly at the regarded as statistically significant. time of randomisation and six months later by The primary analyses were based only on the same radiologist. The following joints were those patients who completed the stipulated evaluated for definite RA change (that is, juxta- trial time and supplied the required data. To articular erosions with a diameter of at least delimit the potential for bias due to various one millimetre, or marked narrowing of the reasons for withdrawal (table 3) we performed joint space combined with subluxation): the additional analyses in which missing data were metacarpophalangeal and proximal inter- input. These outside analyses were based on phalangeal joints; interphalangeal joint of the those completing a shorter trial time and used thumb, wrist (evaluated as one joint); meta- interpolation, extrapolation (carrying last value tarsophalangeal joints; and the interphalangeal forwards), and regression models. These joint of the first toe and the tarsus (evaluated analyses all yielded principally the same http://ard.bmj.com/ as one joint). The number of joints with conclusion with respect to the comparison definite RA changes was counted and the two between treatments. Table 2 Median (25/75 centiles) (at baseline) values during six months of treatment with hydroxychloroquine (HC), sulphasalazine (SASP), or a combination ofthe two (HC+SASP) Drug treatment Month on September 25, 2021 by guest. Protected copyright. 0 1 2 3 4 5 6 ESR (mm/h) HC (n=23) 48 (30/80) 42 (21/73) 44 (17/76) 37 (17/84) 37 (17/76) 31 (10/63) 33 (10/60) SASP (n=17) 48 (34/84) 39 (16/62) 27 (14/59) 27 (9/49) 28 (10/36) 25 (7/32) 16 (9/43) HC+SASP (n=22) 53 (32/67) 41 (17/52) 24 (9/51) 19 (7/32)* 18 (6/32)* 16 (7/25) 16 (9/33) Morning stiffness (minutes) HC (n=23) 60 (30/120) 60 (30/113) 60 (16/120) 60 (6/90) 30 (6/60) 15 (1/60) 15 (1/80) SASP (n=17) 60 (30/120) 45 (26/90) 30 (26/68) 30 (0/41) 15 (4/60) 15 (0/38) 15 (4/38) HC+SASP (n=22) 60 (60/120) 60 (30/60) 30 (0/60) 18 (0/60) 18 (0/60) 5 (0/30) 5 (0/30) Number of swollen joints (0-40) HC (n=23) 9 (5/13) 8 (6/11) 8 (6/12) 7 (4/11)
Load more

Recommended publications
  • A Double-Blind Placebo-Controlled Study of Auranofin in Patients with Psoriatic Arthritis
    158 A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF AURANOFIN IN PATIENTS WITH PSORIATIC ARTHRITIS SIMON CARETTE, ANDRE1 CALIN, JIM P. McCAFFERTY, BRUCE A. WALLIN, and THE AURANOFIN COOPERATING GROUP Two hundred thirty-eight patients with psoriatic treatment was statistically superior to placebo treat- arthritis were entered into a 6-month, multicenter, ment, according to physician’s global assessment and double-blind trial comparing auranofin and placebo. functional scores. A trend in favor of auranofin treat- Polyarthritis (>5 tender joints) was present in 90% of ment was seen for each of the other disease parameters the patients, and 94% were seronegative. Auranofin studied. Psoriasis worsened in 6 auranofin-treated pa- tients and in 3 placebo-treated patients. The incidence Simon Carette, MD: Le Centre Hospitalier de I’Universitt and nature of other side effects were similar to those Laval, Quebec City, Canada: Andrei Calin, MD: Royal National observed in similar trials of patients with rheumatoid Hospital, Bath, UK; Jim P. McCafferty, BSc: Smith Kline & French arthritis. Our observations suggest that the use of Laboratories, Philadelphia, PA; Bruce A. Wallin, MD: Smith Kline & French Laboratories, Philadelphia, PA; Michael H. Weisman, auranofin in the treatment of psoriatic arthritis is safe, MD: University of California, San Diego; Susan G. Perlman, MD: although its therapeutic advantage over treatment with Northwestern University Medical School, Chicago, 1L; Robert F. nonsteroidal antiinflammatory drugs alone is modest. Willkens, MD: University of Washington, Seattle; Stephen J. Farber, MD: Toledo Clinic, Inc., Toledo, OH: H. Ralph Schuma- cher, Jr., MD: University of Pennsylvania, Philadelphia; Suthin Psoriatic arthritis is an inflammatory erosive Songcharoen, MD: Jackson Arthritis Clinic, Jackson, MS; Ronald joint disease characterized by its association with L.
    [Show full text]
  • (Sodium Aurothiomalate Injection, Mfr. Std.) 10, 25 and 50 Mg/Ml Anti
    PRESCRIBING INFORMATION PrMYOCHRYSINE® (sodium aurothiomalate injection, Mfr. Std.) 10, 25 and 50 mg/mL Anti-Rheumatic Agent (disease modifying) sanofi-aventis Canada Inc. Date of Revision: 2150 St. Elzear Blvd. West November 29, 2007 Laval, Quebec H7L 4A8 Submission Control No.: 114637 s-a Version 2.0 dated NAME OF DRUG PrMYOCHRYSINE® Sodium aurothiomalate injection, Mfr. Std. 10, 25 and 50 mg/mL THERAPEUTIC CLASSIFICATION Anti-rheumatic agent (disease modifying) ACTIONS AND CLINICAL PHARMACOLOGY Sodium aurothiomalate exhibits anti-inflammatory, antiarthritic and immunomodulating effects. The predominant clinical effect of MYOCHRYSINE (sodium aurothiomalate) appears to be suppression of the synovitis in the active stage of the rheumatoid disease. The precise mechanism of action is unknown but it has been suggested that the drug may act by inhibiting cell-mediated and humoral immune mechanisms. Additional modes of action include alteration or inhibition of various enzyme systems, suppression of phagocytic activity of macrophage and polymorphonuclear leukocytes, and alteration of collagen biosynthesis. The metabolic fate of sodium aurothiomalate in humans is unknown but it is believed not to be broken down to elemental gold. It is very highly bound to plasma proteins. Sixty to 90% is excreted very slowly by the renal route while 10 to 40% is eliminated in the feces mostly via biliary secretion. The biologic half-life of gold following a single 50 mg dose of parenteral gold has been reported to range from 6 to 25 days. It increases following successive weekly doses. The appearance of clinical effect is slow. It may take at least 8 weeks to become significant and the maximum benefits may not be achieved for at least 6 months.
    [Show full text]
  • Treatment of Psoriatic Arthritis and Rheumatoid Arthritis with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions
    Treatment of Psoriatic Arthritis and Rheumatoid Arthritis with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions PHILIP S. HELLIWELL and WILLIAM J. TAYLOR for the CASPAR Study Group ABSTRACT. Objective. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory diseases of the musculoskeletal system. Although it seems likely that these conditions have a different pathogene- sis, the drugs used to treat them are the same. Our study used a cross-sectional clinical database to com- pare drug use and side-effect profile in these 2 diseases. Methods. The CASPAR study collected data on 588 patients with PsA and 536 controls, 70% of whom had RA. Data on disease modifying drug treatments used over the whole illness were recorded, togeth- er with their outcomes, including adverse events, for RA and PsA. Results. For both diseases methotrexate (MTX) was the most frequently used disease modifying drug (39% of patients with PsA, 30% with RA), with over 70% of patients in both diseases still taking the drug. Other drugs were used with the following frequencies in PsA and RA, respectively: sulfasalazine 22%/13%, gold salts 7%/11%, antimalarial drugs 5%/14%, corticosteroids 10%/17%, and anti-tumor necrosis factor (TNF) drugs 6%/5%. Compared to RA, cyclosporine and anti-TNF agents were less like- ly to be ineffective in PsA. Compared to RA, subjects with PsA were less likely to be taking MTX and more likely to be taking anti-TNF agents. Hepatotoxicity with MTX was more common in PsA, and pul- monary toxicity with MTX was found more often in RA.
    [Show full text]
  • Hedonic Analysis of Arthritis Drugs
    This PDF is a selection from an out-of-print volume from the National Bureau of Economic Research Volume Title: Medical Care Output and Productivity Volume Author/Editor: David M. Cutler and Ernst R. Berndt, editors Volume Publisher: University of Chicago Press Volume ISBN: 0-226-13226-9 Volume URL: http://www.nber.org/books/cutl01-1 Publication Date: January 2001 Chapter Title: Hedonic Analysis of Arthritis Drugs Chapter Author: Iain M. Cockburn, Aslam H. Anis Chapter URL: http://www.nber.org/chapters/c7637 Chapter pages in book: (p. 439 - 462) Arthritis Drugs Iain M. Cockburn and Aslam H. Anis 11.1 Introduction This study examines the market for a group of drugs used to treat rheu- matoid arthritis (RA) during the period 1980-92. Rheumatoid arthritis is a painful, debilitating, and progressive disease which affects millions of people worldwide, with very substantial effects on health and the economy. Regrettably, in contrast to some other major health problems such as heart disease, depression, ulcers, and bacterial infections, this is an area where therapeutic innovations have thus far had comparatively little impact on physicians’ ability to reverse the disease. RA currently has no “cure” and the effectiveness of available treatments is limited. Compared to other drug classes the rate of new product introductions has been slow, and, at the time of writing, there have been no breakthroughs of the same order of significance as the discovery and development of SSRIs for treatment of depression, H, antagonists for ulcers, or ACE inhibitors for hypertension. Nonetheless, the market for RA drugs is far from static.
    [Show full text]
  • PRESCRIBING INFORMATION RIDAURA®Auranofin Capsules
    RIDAURA- auranofin capsule Prometheus Laboratories Inc. ---------- PRESCRIBING INFORMATION RIDAURA® Auranofin Capsules Rx Only RIDAURA® (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea. Therefore, the results of recommended laboratory work (See PRECAUTIONS) should be reviewed before writing each RIDAURA prescription. Like other gold preparations, RIDAURA is only indicated for use in selected patients with active rheumatoid arthritis. Physicians planning to use RIDAURA should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of RIDAURA. In addition, the following precautions should be routinely employed: 1. The possibility of adverse reactions should be explained to patients before starting therapy. 2. Patients should be advised to report promptly any symptoms suggesting toxicity. (See PRECAUTIONS—Information for Patients.) DESCRIPTION RIDAURA (auranofin) is available in oral form as capsules containing 3 mg auranofin. Auranofin is (2,3,4,6-tetra-O-acetyl-1-thio-ß-D-glucopyranosato-S-) (triethyl–phosphine) gold. Auranofin contains 29% gold and has the following chemical structure: Each RIDAURA capsule, with opaque brown cap and opaque tan body, contains auranofin, 3 mg, and is imprinted with the product name RIDAURA. Inactive ingredients consist of benzyl alcohol, cellulose, cetylpyridinium chloride, D&C Red No. 33, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, lactose, magnesium stearate, povidone, sodium lauryl sulfate, sodium starch glycolate, starch, titanium dioxide and trace amounts of other inactive ingredients.
    [Show full text]
  • Chloroquine and Beyond: Exploring Anti-Rheumatic Drugs to Reduce Immune Hyperactivation in HIV/AIDS
    Savarino and Shytaj. Retrovirology (2015) 12:51 DOI 10.1186/s12977-015-0178-0 REVIEW Open Access Chloroquine and beyond: exploring anti‑rheumatic drugs to reduce immune hyperactivation in HIV/AIDS Andrea Savarino* and Iart Luca Shytaj Abstract The restoration of the immune system prompted by antiretroviral therapy (ART) has allowed drastically reducing the mortality and morbidity of HIV infection. However, one main source of clinical concern is the persistence of immune hyperactivation in individuals under ART. Chronically enhanced levels of T-cell activation are associated with sev- eral deleterious effects which lead to faster disease progression and slower CD4+ T-cell recovery during ART. In this article, we discuss the rationale, and review the results, of the use of antimalarial quinolines, such as chloroquine and its derivative hydroxychloroquine, to counteract immune activation in HIV infection. Despite the promising results of several pilot trials, the most recent clinical data indicate that antimalarial quinolines are unlikely to exert a marked beneficial effect on immune activation. Alternative approaches will likely be required to reproducibly decrease immune activation in the setting of HIV infection. If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations. Keywords: Immune activation, HIV latency, Chloroquine, Hydroxychloroquine, Anti-rheumatic, Clinical trials, Auranofin Background acidic organelles, chloroquine exerts both direct antiviral The quest for clinical candidates to counteract immune effects on enveloped viruses and decreases activation of activation has become a “hot topic” in AIDS research, several cell types involved in the immune response.
    [Show full text]
  • Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
    viruses Review Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak Zheng Yao Low 1 , Isra Ahmad Farouk 1 and Sunil Kumar Lal 1,2,* 1 School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia; [email protected] (Z.Y.L.); [email protected] (I.A.F.) 2 Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia * Correspondence: [email protected] Received: 3 July 2020; Accepted: 21 August 2020; Published: 22 September 2020 Abstract: Traditionally, drug discovery utilises a de novo design approach, which requires high cost and many years of drug development before it reaches the market. Novel drug development does not always account for orphan diseases, which have low demand and hence low-profit margins for drug developers. Recently, drug repositioning has gained recognition as an alternative approach that explores new avenues for pre-existing commercially approved or rejected drugs to treat diseases aside from the intended ones. Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well accessed and approved by regulatory authorities. The greatest advantage of drug repositioning is that it breathes new life into the novel, rare, orphan, and resistant diseases, such as Cushing’s syndrome, HIV infection, and pandemic outbreaks such as COVID-19. Repositioning existing drugs such as Hydroxychloroquine, Remdesivir, Ivermectin and Baricitinib shows good potential for COVID-19 treatment. This can crucially aid in resolving outbreaks in urgent times of need.
    [Show full text]
  • Gold Levels Produced by Treatment with Auranofin and Sodium Aurothiomalate
    Ann Rheum Dis: first published as 10.1136/ard.42.5.566 on 1 October 1983. Downloaded from Annals ofthe Rheumatic Diseases, 1983, 42, 566-570 Gold levels produced by treatment with auranofin and sodium aurothiomalate D. LEWIS,' H. A. CAPELL,1 C. J. McNEIL,2 M. S. IQBAL,2 D. H. BROWN, 2 AND W. E. SMITH2 From the 1CentreforRheumatic Diseases, University DepartmentofMedicine, Baird Street, Glasgow G4 OEH, and the 2Department ofPure and Applied Chemistry, University ofStrathclyde, Glasgow GJ IXL SUMMARY Sixty-three patients with rheumatoid arthritis were randomly divided into 3 groups, and treated with either sodium aurothiomalate (Myocrisin), auranofin, or placebo. Gold levels in whole blood, plasma, and haemolysate were measured serially along with clinical and laboratory para- meters of efficacy. Auranofin produced a higher ratio of haemolysate to plasma gold than Myocrisin, and it appears that the affinity of the red cell for gold is reduced during therapy with auranofin. Gold levels did not correlate with changes in the pain score, erythrocyte sedimentation rate, and C-reactive protein, nor with the development of toxicity. In the Myocrisin group the haemolysate gold level achieved was dependent on the number of cigarettes smoked. In the auranofin group there was no such correlation, but the haemolysate gold level was higher for smokers than non-smokers. The likely action of gold is discussed. copyright. Gold compounds have been used in the treatment of The purpose of the present study was to measure rheumatoid arthritis for over 50 years, and theirplace the distribution ofgold in the blood of patients receiv- in clinical practice is firmly established.' 2 However, ing Myocrisin or auranofin, both in order to deter- there remains a need to monitor the use of these mine whether or not parameters such as haemolysate compounds very carefully to establish efficacy and to gold or the ratio of haemolysate to plasma gold are anticipate the onset of any toxic reaction which may correlated with efficacy or toxicity and to improve http://ard.bmj.com/ occur.
    [Show full text]
  • Investigation of Auranofin and Gold-Containing Analogues Antibacterial Activity Against Multidrug-Resistant Neisseria Gonorrhoea
    www.nature.com/scientificreports OPEN Investigation of auranofn and gold- containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae Ahmed Elkashif1 & Mohamed N. Seleem1,2* Neisseria gonorrhoeae represents an urgent public health threat due to the rapid emergence of resistance to current antibiotics and the limited number of anti-gonococcal agents currently in clinical trials. This study utilized a drug repositioning strategy to investigate FDA-approved gold-containing drugs against N. gonorrhoeae. Auranofn, sodium aurothiomalate and aurothioglucose inhibited 48 clinical isolates of N. gonorrhoeae including multidrug-resistant strains at a concentration as low as 0.03 µg/mL. A time-kill assay revealed that auranofn exhibited rapid bactericidal activity against N. gonorrhoeae. Moreover, both sodium aurothiomalate and aurothioglucose did not inhibit growth of vaginal protective commensal lactobacilli. Auranofn, in combination with azithromycin, ceftriaxone, cefxime or tetracycline showed an additive efect against four N. gonorrhoeae strains, suggesting the possibility of using auranofn in dual therapy. Moreover, auranofn reduced the burden of intracellular N. gonorrhoeae by over 99% outperforming the drug of choice ceftriaxone. Auranofn was found superior to ceftriaxone in reducing the secretion of the pro-infammatory cytokine IL-8 by endocervical cells infected with N. gonorrhoeae. Furthermore, auranofn exhibited a prolonged post-antibiotic efect over 10 h, as well as inability to generate resistant mutants. Overall, the current study suggests that repurposing gold-containing drugs, like auranofn, for treatment of gonorrhea warrants further investigation. Neisseria gonorrhoeae infects both the human male and female reproductive tracts causing the sexually trans- mitted infection gonorrhea. Gonorrhea is the second most common notifable disease in the United States of America, according to the Centers for Disease Control and Prevention (CDC)1,2.
    [Show full text]
  • Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)
    HEDIS 2016 CRITERIA Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) Q: Which members are included in the sample? A: Adults 18 years and older with a diagnosis of rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease-modifying anti- rheumatic drug (DMARD) in 2015. Q: What codes are used? A: Please reference attached sample codes; reference Value Set Directory for additional codes Q: What documentation is needed in the medical record? A: None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes. Q: What documentation is needed in the medical record? A: Evidence from claim/encounter/pharmacy data A date of service for any outpatient visit or a non-acute inpatient discharge with a diagnosis of rheumatoid arthritis, and a prescription for DMARD in 2015. DMARDs: Description Prescription 5-Aminosalicylates Sulfasalazine Alkylating agents Cyclophosphamide Aminoquinolines Hydroxychloroquine Anti-rheumatics Auranofin Leflunomide Penicillamine Gold sodium Methotrexate thiomalate Immunomodulators Abatacept Certolizumab Rituximab Adalimumab pegol Tocilizumab Anakinra Etanercept Certolizumab Golimumab Infliximab Immunosuppressive Azathioprine Cyclosporine Mycophenolate agents Janus kinase (JAK) Tofacitinib inhibitor Tetracyclines Minocycline HEDIS-November 2015 Page 15 HEDIS 2016 CRITERIA Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) Q: How to improve score for this HEDIS measure?
    [Show full text]
  • Sulfasalazine Induced Immune Thrombocytopenia in a Patient with Rheumatoid Arthritis
    Clin Rheumatol DOI 10.1007/s10067-016-3420-9 CASE BASED REVIEW Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis Nehal Narayan1 & Shirley Rigby 2 & Francesco Carlucci1 Received: 11 September 2016 /Accepted: 16 September 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Sulfasalazine has long been used for the treatment Our patient, a 67 year old Caucasian man, presented with of rheumatoid arthritis and is often chosen as a first-line symmetrical synovitis of knees, shoulders, and small joints of treatment. Here, we report a case of sulfasalazine-induced the hands. A diagnosis of seronegative RA was made. ANA autoimmune thrombocytopenia and review the mechanisms was negative at time of diagnosis. He was commenced on behind drug-induced immune thrombocytopenia (DITP) and sulfasalazine, with remission of arthritis 4 months later. His the approach to its diagnosis and management. other medication consisted of diclofenac 50 mg, which he took up to twice a day, as needed. Two years after diagnosis, at a routine follow up, it was noted that his platelet count had Keywords Rheumatoid arthritis (RA) . Rheumatic diseases . been steadily declining for 3 months, from an average count of Thrombocytopenia . Autoantibodies . Tissues or models . 230 × 109/L to 90 × 109/L. The patient himself was well, Hematologic diseases . Blood platelets disorders without rash, symptoms of bleeding, or history of recent ill- ness and his RA remained in remission. Medication was un- changed. Examination was unremarkable; the patient was afe- Sulfasalazine (SSZ) has been used for the treatment of rheu- brile, with no evidence of purpura, or bleeding, and no lymph- matoid arthritis (RA) for decades.
    [Show full text]
  • HIV and COVID-19 No. 6
    ISSN 1472-4863 HTB no. 9 – HIV and COVID-19 no.hiv 6 treatmen hiv bulletin+(e) treatmen bulletin+(e) AIDS 2020; HIV and COVID-19 supp. 6 (22 July 2020) C O N T E N T S EDITORIAL: HIV and COVID-19 issue 6 3 i-BASE APPEAL • Please support i-Base with £5 or £10 a month... CONFERENCE REPORTS 3 IAS COVID-19 Conference (IAS COVID-19), 10 – 11 July 2020, virtual meeting • Introduction • Conference opening: making sense of the science • HepC drugs works against COVID-19: faster recovery and reduced mortality from generic sofosbuvir and daclatasvir • Predictors of response to remdesivir in GS-5773 COVID-19 study CONFERENCE REPORTS 8 23rd International AIDS Conference (AIDS 2020), 6 – 10 July 2020, virtual meeting. • Introduction: AIDS2020 online • Navigating the website: PDF programme and abstract book... • Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study • Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS • ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF - no evidence of a plateau • Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes • Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART • Long-acting cabotegravir injections effective as HIV PrEP in gay men and transgender women: results from HPTN 083 • Case report of short-term HIV remission from adding oral nicotinamide to intensified ART • New HIV remission case report at AIDS 2020: full report ANTIRETROVIRALS 20 • FDA approves fostemsavir for multidrug resistant HIV in the US HIV: PREVENTION 21 • UK government cuts HIV PrEP budget in England by a third Contents continued inside..
    [Show full text]